What happened?
The U.S. HHS has determined COVID-19 EUA declarations no longer apply; a 180‑day transition runs to 2026‑12‑26. FDA issued guidance for manufacturers to submit marketing applications (for example, 510(k)) and said it may not object to continued distribution in some cases while submissions are under review. CMS will allow labs to keep using EUA tests consistent with prior authorizations until product expiry.
Why does it matter?
The change ends special EUA status and shifts COVID tests toward standard FDA marketing pathways. Laboratories must identify which tests they use, ask manufacturers whether they will pursue clearance, and plan for replacing tests if manufacturers do not seek traditional authorisation.
How to interpret the evidence
Audience: clinical and public‑health laboratories and testing professionals. Material uncertainty: some manufacturers may or may not submit FDA marketing applications; continued use depends on FDA/CMS discretion and product expiry. This is a U.S. federal action; applicability in the EU or Malta depends on local regulators and manufacturer supply or authorisations — check local rules and suppliers.
What remains uncertain?
This advisory is not an immediate ban on COVID tests, nor clinical treatment guidance. It does not state that specific tests are available in the EU or Malta, nor does it change clinical use instructions or dosing. Labs should not assume automatic local regulatory alignment without checking national requirements.
Medical News provides general health education. Individual treatment decisions depend on your circumstances and the advice of your clinical team.
This summary was prepared with AI assistance and checked automatically against the linked primary source. It has not been individually reviewed by a clinician.